NCT05616624View on ClinicalTrials.gov

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2033

Conditions
Non Small Cell Lung CancerNon-small Cell Lung CancerSmall-cell Lung CancerSmall Cell Lung Carcinoma
Interventions
DRUG

ADI-PEG 20

-Given 60 minutes (+/- 15 minutes) prior to docetaxel

DRUG

Gemcitabine

-Given over the course of 90 minutes (+/- 10 minutes)

DRUG

Docetaxel

-Given over the course of 60 minutes (+/- 10 minutes)

Trial Locations (3)

22031

RECRUITING

Inova Schar Cancer Institute, Fairfax

60611

RECRUITING

Northwestern University, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Polaris Group
All Listed Sponsors
collaborator

Polaris Group

INDUSTRY

lead

Washington University School of Medicine

OTHER